SNTI 株価分析 — Senti Biosciences Inc (Healthcare >> Biotechnology)
SNTI に関するよくある質問
SNTIのROE(自己資本利益率)は?
Senti Biosciences IncのROEは-2,009.63%です。
SNTIの配当利回りは?
Senti Biosciences Incの配当利回りは0.00%です。
SNTIの品質スコア(Quality Score)は?
当社のAIはSNTIの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SNTIは今が買い時ですか?
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SNTIはどのセクターに属しますか?
Senti Biosciences IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
SNTI AI Analysis Summary
Our AI summary for SNTI: Senti Biosciences Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -2,009.63%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.37
Price
-0.01
(-3.12%)
Day Change
|
|
|---|
SNTI, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.37 |
| PBV / Sector |
4.67 / 44,105.10
|
| Earning Per Share | -1.60 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.19 M
GREAT
|
| Average 1W Daily Value |
0.05 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:42 |
| Symbol | SNTI |
| Name | SENTI BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 31.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.99 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2 Corporate Drive, South San Francisco, CA, United States, 94080
Phone: 650 239 2030
Website: https://www.sentibio.com
Sector: Healthcare >> Biotechnology
Description: Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google